Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Table 1 Basic characteristics of total patients with Bronchiolitis Obliterans Syndrome (BOS)

Characteristics	(N = 61)
Recipient sex, male	33/61 (54.1 %)
Recipient age	46.5 ± 12.3
Donor sex, male	32/59 (54.2 %)
Donor age^a	37.1 ± 11.7
Hematologic malignancy
AML	17 (27.9 %)
ALL	20 (32.8 %)
CML	1 (1.6 %)
NHL	2 (3.3 %)
MDS	21 (34.4 %)
Donor type
Unrelated	28 (45.9 %)
Sibling	25 (41.0 %)
FMT	8 (13.1 %)
HLA
full-match	43 (70.5 %)
mismatch	18 (29.5 %)
Stem cell source
PB	51 (83.6 %)
BM	8 (13.1 %)
Cord	2 (3.3 %)
Time from HSCT to BOS diagnosis, days	434.0 (275.0–835.5)
Acute GVHD	39 (63.9 %)
Chronic GVHD (except lung)	61 (100.0 %)
Skin	31 (50.8 %)
Oral	42 (68.9 %)
Eyes	36 (59.0 %)
Liver	10 (16.4 %)
Joint	3 (4.9 %)
Maximal score of chronic GVHD (except lung)^b	1 (1–2)
Systemic steroid use	33 (54.1 %)
Steroid dose, mg (equivalent dose of prednisolone)	2.5 (0.0–15.0)
Tacrolimus	18 (29.5 %)
Cyclosporin	9 (14.8 %)
Mycophenolate mofetil	18 (29.5 %)

^aAge of two donors were missed because of cord blood transplantation (N = 59). ^bEach organ was scored as 0, 1, 2 or 3 based on the degree of functional impairment. Data represent the mean ± SD, median (IQR) or n (%). BOS bronchiolitis obliterans syndrome, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease

ISSN: 1465-993X